Show simple item record

dc.contributor.authorZachariah, R
dc.contributor.authorMassaquoi, M
dc.date.accessioned2008-01-31T16:19:21Z
dc.date.available2008-01-31T16:19:21Z
dc.date.issued2006-04
dc.identifier.citationCotrimoxazole prophylaxis for HIV-positive TB patients in developing countries. 2006, 36 (2):79-82notTrop Doct
dc.identifier.issn0049-4755
dc.identifier.pmid16611438
dc.identifier.doi10.1258/004947506776593314
dc.identifier.urihttp://hdl.handle.net/10144/17283
dc.description.abstractDespite provisional recommendations from the World Health Organization and UNAIDS that cotrimoxazole (CTX) prophylaxis be offered to all individuals living with AIDS, including HIV-positive patients with TB, its routine use in developing countries particularly Africa has been minimal. Concerns were expressed regarding its effectiveness in areas of high bacterial resistance, that its widespread use might substantially increase bacterial cross-resistance in the community and that this intervention might promote resistance of malaria parasites to sulphadoxine-pyrimethamine. We review the current evidence on the above concerns and highlight the main operational considerations related to implementing CTX prophylaxis as a basic component of care for HIV-positive TB patients in developing countries.
dc.language.isoen
dc.relation.urlhttp://td.rsmjournals.com
dc.rightsReproduced on this site with the permission of Royal Society of Medicine Press, London (www.rsmpress.co.uk/td.htm)en_GB
dc.subject.meshAIDS-Related Opportunistic Infections
dc.subject.meshAdult
dc.subject.meshAfrica South of the Sahara
dc.subject.meshAnti-Infective Agents
dc.subject.meshChild
dc.subject.meshDrug Resistance
dc.subject.meshHumans
dc.subject.meshMalaria
dc.subject.meshTrimethoprim-Sulfamethoxazole Combination
dc.subject.meshTuberculosis
dc.titleCotrimoxazole prophylaxis for HIV-positive TB patients in developing countries.
dc.contributor.departmentMedecins sans Frontieres, Operational Research HIV-TB, Medical department, Brussels Operational Center, 68 Rue de Gaspench, L-1617 Luxemburg. zachariah@internet.lu
dc.identifier.journalTropical Doctor
refterms.dateFOA2019-03-04T09:03:38Z
html.description.abstractDespite provisional recommendations from the World Health Organization and UNAIDS that cotrimoxazole (CTX) prophylaxis be offered to all individuals living with AIDS, including HIV-positive patients with TB, its routine use in developing countries particularly Africa has been minimal. Concerns were expressed regarding its effectiveness in areas of high bacterial resistance, that its widespread use might substantially increase bacterial cross-resistance in the community and that this intervention might promote resistance of malaria parasites to sulphadoxine-pyrimethamine. We review the current evidence on the above concerns and highlight the main operational considerations related to implementing CTX prophylaxis as a basic component of care for HIV-positive TB patients in developing countries.


Files in this item

Thumbnail
Name:
Trop Doc 2 zach Review CO.pdf
Size:
180.1Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record